Blepharoplasty patients report statistically significant improvement of quality of life
Researchers used both the vision-specific NEI VFQ-25 and a generic health-related instrument, the EQ-5D, to examine the effects of blepharoptosis and its surgical repair on quality of life for 48 adults.
Aflibercept promises excellent visual outcomes for patients with exudative AMD
A review of clinical trial results indicates that monthly and bimonthly aflibercept treatments were noninferior to monthly ranibizumab at preventing vision loss, with comparable vision gains and safety. Aflibercept requires fewer injections and is less costly.
Patients with VMID are not necessarily treatment resistant for AMD
A study that reviewed patients with vitreomacular interface disease (VMID) undergoing treatment for exudative AMD found that anti-vascular endothelial growth factor therapy improved best-corrected visual acuity and decreased central foveal thickness despite continued traction.
Residual haze partially improves after DSEK for Fuchs dystrophy
A study of eyes with Fuchs dystrophy indicates that visual function after Descemet stripping with endothelial keratoplasty is affected by residual haze in the anterior host cornea. The haze does not affect visual acuity.